Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

Ophthalmic Pharmaceuticals, Market Analysis, Forecasts and Dynamics - 2009-2023

BioNewsCast Press Release Distribution Service

Statins: The World Market, 2009-2024

Liver Cancer Drug Pipeline Update 2008

Bioinformatics Markets

New Products

Live Cell & Kinetic HCS Imaging Trends 2008

2008 Trends to Watch: Healthcare Technology

2009 Trends to Watch: Healthcare Technology

Biosimilars Series: Stakeholder Analysis

Biotech M&A Strategies: Deal assessments, trends and future prospects

Building a Network of Networks to Achieve Interoperability in Healthcare (Strategic Focus)

Business Trends - Healthcare Technology (Customer Focus)

Claims Processing for Healthcare Payers (Market Model)

Clinical Decision Support in Healthcare - One step closer to the Omniscient Clinician (Strategic Focus)

Commercial and Pipeline Insight: ADHD - Immature adult market continues to offer greatest commercial potential

BioPortfolio | Datamonitor Healthcare Reports | Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share

Bausch and Lomb's Contact Lens Solution Withdrawal - ReNu MultiPlus likely to struggle in attempt to regain market share

In May 2006 Bausch & Lomb's ReNu with MoistureLoc contact lens solution was permanently withdrawn from markets worldwide due to an outbreak of a fungal eye infection. For a large market player, the loss of a new revenue driver and the negative publicity surrounding the event is likely to have a significant impact on future success, as well as implications for other companies in the sector.

Scope

> This report analyzes the market outlook in the aftermath of the withdrawal of Bausch & Lomb's ReNu with MoistureLoc contact lens solution

> Datamonitor interviewed eight optometrists from the US and the EU in the course of research

Highlights

> Bausch & Lomb's explanation of the cause of infection is in line with suspicions of interviewed optometry experts that the revolutionary make-up of MoistureLoc's formula made it susceptible to external factors that could elevate infection risk.

> Moving forward, US practitioners will likely put more emphasis on patient adherence to particular recommended brands, and patients are likely to be less price-sensitive, favoring competitors over Bausch & Lomb's older contact lens solution, ReNu MultiPlus.

> Collateral damage to Bausch & Lomb's eye care franchise in European markets is expected to be minimal.

Reasons to Purchase

> Understand the implications of Bausch & Lomb's product recall through in-depth analysis based on interviews with leading experts

> Anticipate likely changes in the future market dynamics for contact lens solutions following the withdrawal of ReNu with MoistureLoc

29-Aug-06 PDF 12
Table of Contents
Price: $3,800.00 / €2,726.88

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions